Bayer, Raptor reel in endorsements from EMA for new therapies

The European Medicines Agency's experts have backed approval for two drugs that have already gained green lights for the U.S. market. Bayer won the EU agency's endorsement for Stivarga, a targeted drug for colorectal cancer, which is partnered with Onyx Pharmaceuticals ($ONXX). Raptor Pharmaceuticals garnered the EMA's blessing for marketing its therapy Procysbi for the most common form of a rare genetic disease called cystinosis. As usual, the European Commission will decide within months whether to take the advice of the EMA. Stivarga news | Procysbi news

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.